[1] SZUDY-SZCZYREK A, MLAK R, MIELNIK M, et al. Prognostic value of pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in multiple myeloma patients treated with thalidomide-based regimen[J]. Ann Hematol, 2020, 99(12): 2881. doi: 10.1007/s00277-020-04092-5
[2] 彭福, 骆鹏飞, 李雷. 乳腺癌病人术前炎性指标与临床病理特征的相关性分析[J]. 蚌埠医学院学报, 2021, 46(9): 1208. doi: 10.13898/j.cnki.issn.1000-2200.2021.09.014
[3] SUN L, JIN Y, HU W, et al. The impacts of systemic immune-inflammation index on clinical outcomes in gallbladder carcinoma[J]. Front Oncol, 2020, 10: 554521. doi: 10.3389/fonc.2020.554521
[4] GUO W, CAI S, ZHANG F, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer[J]. Thorac Cancer, 2019, 10(4): 761. doi: 10.1111/1759-7714.12995
[5] 《中国多发性骨髓瘤诊治指南(2020年修订)》发布[J]. 中华医学信息导报, 2020, 35(11): 12.
[6] KUMAR SK, DISPENZIERI A, LACY MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients[J]. Leukemia, 2014, 28(5): 1122. doi: 10.1038/leu.2013.313
[7] 刘文斌, 曹广文. 癌症进化发育学: 基于炎-癌转化研究的新学说[J]. 中国肿瘤生物治疗杂志, 2017, 24(2): 103.
[8] MACKEY JBG, COFFELT SB, CARLIN LM. Neutrophil maturity in cancer[J]. Front Immunol, 2019, 10: 1912. doi: 10.3389/fimmu.2019.01912
[9] TREFFERS LW, HIEMSTRA IH, KUIJPERS TW, et al. Neutrophils in cancer[J]. Immunol Rev, 2016, 273(1): 312. doi: 10.1111/imr.12444
[10] GRECIAN R, WHYTE MKB, WALMSLEY SR. The role of neutrophils in cancer[J]. Br Med Bull, 2018, 128(1): 5. doi: 10.1093/bmb/ldy029
[11] ISEKI Y, SHIBUTANI M, MAEDA K, et al. The impact of the preoperative peripheral lymphocyte count and lymphocyte percentage in patients with colorectal cancer[J]. Surg Today, 2017, 47(6): 743. doi: 10.1007/s00595-016-1433-2
[12] MAMI-CHOUAIB F, BLANC C, CORGNAC S, et al. Resident memory T cells, critical components in tumor immunology[J]. J Immunother Cancer, 2018, 6(1): 87. doi: 10.1186/s40425-018-0399-6
[13] 李玉陶, 刘宁洒, 李护君, 等. 血小板分布宽度与血小板计数比值对多发性骨髓瘤预后分析[J]. 徐州医科大学学报, 2021, 41(7): 493. doi: 10.3969/j.issn.2096-3882.2021.07.005
[14] JOMRICH G, GRUBER ES, WINKLER D, et al. Systemic immune-inflammation index (SII) predicts poor survival in pancreatic cancer patients undergoing resection[J]. J Gastrointest Surg, 2020, 24(3): 610. doi: 10.1007/s11605-019-04187-z
[15] 胡华芳, 辛道, 孟祥瑞, 等. 系统免疫炎症指数对局部晚期食管鳞癌的预后价值[J]. 肿瘤基础与临床, 2020, 33(1): 38.
[16] KIM DS, YU ES, KANG KW, et al. Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma[J]. Korean J Intern Med, 2017, 32(4): 711. doi: 10.3904/kjim.2016.054
[17] SOLMAZ MEDENI S, ACAR C, OLGUN A, et al. Can neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio at day +100 be used as a prognostic marker in multiple myeloma patients with autologous transplantation?[J]. Clin Transplant, 2018, 32(9): e13359. doi: 10.1111/ctr.13359
[18] 赵泽昊, 孙海英. 初诊多发性骨髓瘤患者血液炎症指标与预后的相关性分析[J]. 现代肿瘤医学, 2019, 27(21): 3878.
[19] SHI L, QIN X, WANG H, et al. Elevated neutrophil-to-lymphocyte ratio and monocyte-to-lymphocyte ratio and decreased platelet-to-lymphocyte ratio are associated with poor prognosis in multiple myeloma[J]. Oncotarget, 2017, 8(12): 18792. doi: 10.18632/oncotarget.13320